Seizure Drugs: Adult Efficacy Data May Be Extrapolated To Pediatric Patients
Executive Summary
US FDA final guidance on partial onset seizure drugs reflects only one major change from an earlier draft version: the lowering of the youngest age for which extrapolation of efficacy is appropriate, from four years to two years.
You may also be interested in...
Lyrica Generics Likely Delayed By A Pfizer Labeling Supplement
US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.
Accelerated Approval: Potential Sources Of Confirmatory Evidence Weighed At Tofersen Review
‘Clear signal’ in the ATLAS study of presymptomatic, SOD1 mutation carriers could provide evidence needed to confirm tofersen’s benefit in symptomatic ALS patients, FDA’s Teresa Buracchio says, adding that getting confirmatory evidence from the VALOR open-label extension 'could be a little more tricky.'
Accelerated Approval Is US FDA Panel’s Preferred Path For Biogen/Ionis’s Tofersen In ALS
Advisory committee unanimously concludes that the reduction in plasma neurofilament light chain concentration is reasonably likely to predict clinical benefit in SOD1-ALS, but majority of panelists say convincing evidence of efficacy to support regular approval has not been demonstrated.